Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 07, 2016 1:45 PM ET

Pharmaceuticals

Company Overview of Apotex Inc.

Company Overview

Apotex Inc., a pharmaceutical company, engages in the research and development, manufacture, distribution, and sale of generic pharmaceuticals in Canada and internationally. It offers medicines in various dosage forms. The company serves patients, healthcare providers, payers, and governments. It offers its products through pharmacies and healthcare facilities. Apotex Inc. has a strategic alliance with Panacea Biotec. The company was founded in 1974 and is based in Toronto, Canada with additional offices in Saudi Arabia. It has facilities in Montreal, Richmond Hill, Toronto, Etobicoke, Mississauga, Brantford, Windsor, Winnipeg, London, Calgary, and Vancouver, Canada; and subsidiaries, joint ...

150 Signet Drive

Toronto, ON M9L 1T9

Canada

Founded in 1974

Phone:

800-268-4623

Fax:

800-609-9444

Key Executives for Apotex Inc.

Chief Executive Officer and President
Founder and Chairman of the Board
President of Apotex International
President of Global Generics
President of Global Specialty Pharma
Compensation as of Fiscal Year 2015.

Apotex Inc. Key Developments

Vanda Pharmaceuticals Inc. Files Four Separate Patent Infringement Lawsuits against Roxane Laboratories, Inc., Inventia Healthcare Pvt. Ltd., Taro Pharmaceuticals, U.S.A., Inc./Taro Pharmaceuticals Industries Ltd., Apotex Corp. and Apotex

On October 13, 2015, Vanda Pharmaceuticals Inc. filed four separate patent infringement lawsuits in the United States District Court for the District of Delaware asserting U.S. Patent No. 9,138,432 (432 Patent), recently listed on the U.S. Food and Drug Administration (FDA) publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Two of these lawsuits join existing litigations against the Fanapt Abbreviated New Drug Application (ANDA) filers, Roxane Laboratories, Inc. and Inventia Healthcare Pvt. Ltd. The other two lawsuits are filed against new ANDA filers, Taro Pharmaceuticals, U.S.A., Inc./Taro Pharmaceuticals Industries Ltd. and Apotex Inc., in which the company is additionally asserting the company's U.S. Patent No. 8,586,610 (610 Patent). The first of these lawsuits, which was filed against Roxane, seeks an adjudication that Roxane has infringed the 432 Patent by submitting to the FDA an ANDA for a generic version of Fanapt prior to the expiration of the 432 Patent in September 2025. This lawsuit is separate from the company's two pending cases against Roxane relating to the 610 Patent and Aventisub LLC's U.S. Patent No. RE39,198, which are scheduled to be tried together in a four-day bench trial beginning on February 29, 2016. The second of these lawsuits, which was filed against Inventia, seeks an adjudication that Inventia has infringed the 432 Patent by submitting to the FDA an ANDA for a generic version of Fanapt prior to the expiration of the 432 Patent in September 2025. This lawsuit is separate from the company's pending case against Inventia relating to the 610 Patent, which is scheduled to be tried in a four-day bench trial beginning on January 17, 2017. The third of these lawsuits, which was filed against Taro, seeks an adjudication that Taro has infringed one or more claims of the 432 Patent and the 610 Patent by submitting to the FDA an ANDA for a generic version of Fanapt prior to the expiration of the 432 Patent in September 2025 and the 610 Patent in November 2027. The fourth of these lawsuits, which was filed against Apotex and Apotex Corp., seeks an adjudication that Apotex has infringed one or more claims of the 432 Patent and the 610 Patent by submitting to the FDA an ANDA for a generic version of Fanapt prior to the expiration of the 432 Patent in September 2025 and the 610 Patent in November 2027.

Apotex Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-04-2015 09:30 AM

Apotex Inc. Presents at Bloom Burton & Co. Inc. Healthcare Investor Conference, May-04-2015 09:30 AM. Venue: Sheraton Centre Toronto Hotel (Corner of York and Queen St. West), Toronto, Ontario, M5H 3M9, Canada.

Apotex Announces Structural Realignment

Apotex Inc. has announced realignment in its structure and operating model. The objective of the realignment is to better serve customers through the establishment of defined lines of business by aligning internal process streams in support of company strategies. Under the new structure, Apotex will now operate along 3 core Lines of Business: Global Generics; Global Specialty Pharma; and Global Active Pharmaceutical Ingredients. Global Generics is responsible for the delivery of the generics portfolio arising out of the Apotex group of companies and third parties to all global markets. Global Specialty Pharma is responsible for the development, manufacturing and global commercialisation of Biosimilars and other specialty products made by Apotex or supplied by third parties.

Similar Private Companies By Industry

Company Name Region
Liphorus Pharmaceuticals Inc. Americas
Abamont Pharma Inc. Americas
Eastwood Bio-Medical Research Inc. Americas
International Herbs Medical Marijuana Ltd. Americas
Vida Cannabis Corp. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Apotex Inc., please visit www.apotex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.